OMDM-2.

From the series of aromatic analogues of N-oleoylethanolamine described in 2003 by Ortar et al., OMDM-2 targets the uptake of anandamide rather than a receptor: it blocks it with a Ki of 3.0 µM in RBL-2H3 cells, without inhibiting FAAH (Ki above 50 µM) and without notable affinity for CB1 (Ki of 5 µM or more), CB2 (above 10 µM) or VR1 (EC50 of 10 µM or more). In rats, 5 mg/kg intraperitoneally strengthened the motor-inhibiting effects of an ineffective dose of anandamide and, from 1 to 10 mg/kg, lengthened the time spent on a hot plate; at 5 mg/kg intravenously, it reduced hindlimb spasticity in mice with chronic relapsing experimental allergic encephalomyelitis (de Lago et al. 2004). Perfused into the paraventricular thalamic nucleus of rats (10 to 30 µM), it increased sleep, decreased waking and reduced extracellular dopamine in the nucleus accumbens (Murillo-Rodríguez et al. 2013). In rodents, systemic administration decreased social interaction, an effect exacerbated by AM251 and reversed by CP55,940, which is consistent with reduced activation of presynaptic CB1 receptors and with the idea that blocking transport might also prevent the release of endocannabinoids (Seillier and Giuffrida 2018). The existence of the transporter itself remains debated (Ligresti et al. 2010). All these data are preclinical.

Source

A synthetic molecule, an aromatic analogue of N-oleoylethanolamine (an amide of oleic acid and a tyrosine-derived amino alcohol), absent from cannabis and from any living organism. A research reagent.

No known biosynthetic pathway: the molecule is produced by no organism; it is a synthetic oleic acid amide.

European Union

A laboratory reagent; no European Union classification specific to the molecule was found in the sources consulted. Its status depends on the national law of each Member State.

France

Not classified: absent from the ANSM list of narcotics (consolidated version updated 16/02/2026). A fatty acid amide without an indole, indazole or benzo[c]chromene nucleus, it falls under none of the generic entries of Annex IV. The absence of classification is not a marketing authorisation.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

ECS pharmacological tool › Transport inhibitor

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

No dedicated article.

1. 1Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V, Novel selective and metabolically stable inhibitors of anandamide cellular uptake, Biochem Pharmacol 2003 (new tab)PMID 12732359
2. 2de Lago E et al., In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake, Eur J Pharmacol 2004 (new tab)PMID 14744610
3. 3Murillo-Rodríguez E et al., The administration of endocannabinoid uptake inhibitors OMDM-2 or VDM-11 promotes sleep and decreases extracellular levels of dopamine in rats, Physiol Behav 2013 (new tab)PMID 23238438
4. 4Seillier A, Giuffrida A, The cannabinoid transporter inhibitor OMDM-2 reduces social interaction: further evidence for transporter-mediated endocannabinoid release, Neuropharmacology 2018 (new tab)PMID 29169961
5. 5Ligresti A et al., Exploiting nanotechnologies and TRPV1 channels to investigate the putative anandamide membrane transporter, PLoS One 2010 (new tab)PMID 20422025
6. 6ANSM, Consolidated list of substances classified as narcotics, updated 16 February 2026, annex IV (new tab)
7. 7PubChem, compound CID 6604915 (OMDM-2) (new tab)

SMILES

CCCCCCCC/C=C\CCCCCCCC(=O)N[C@H](CC1=CC=C(C=C1)O)CO

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.